Citius Pharmaceuticals Inc (OQ:CTXR)

Business Focus: Biotechnology & Medical Research

Mar 22, 2024 09:31 am ET
Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
NEW YORK, March 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VLD, NVFY, INDI, CTXR, and RNAZ.
Mar 12, 2024 10:30 am ET
Sidoti Events, LLC's Virtual March Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 13-14, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Feb 26, 2024 06:30 am ET
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
CRANFORD, N.J., Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company filed a Form S-3 shelf registration on February 23, 2024 with the Securities and Exchange Commission to replace its currently effective shelf registration statement that expires in April 2024 pursuant to SEC rules.
Feb 23, 2024 07:30 am ET
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
CRANFORD, N.J., Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will present at the BIO CEO and Investor Conference on February 26-27, 2024, and the Sidoti Small-Cap Virtual Conference on March 13-14, 2024.
Feb 14, 2024 03:30 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date
Feb 14, 2024 07:01 am ET
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission
Jan 23, 2024 07:30 am ET
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024
Jan 02, 2024 07:30 am ET
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
Nov 14, 2023 08:55 am ET
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 15-16, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Nov 09, 2023 07:30 am ET
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
CRANFORD, N.J., Nov. 9, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on November 15, 2023.
Oct 31, 2023 08:45 am ET
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor microenvironment
Oct 24, 2023 07:30 am ET
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition (“TenX”) (NASDAQ: TENKU), a publicly traded...
Oct 24, 2023 07:30 am ET
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction
Sep 21, 2023 09:35 am ET
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand...
Sep 18, 2023 04:30 pm ET
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
CRANFORD, N.J., Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir, a long-time member of the Citius Board. Mr. Mazur was originally scheduled to present at the Sidoti Small-Cap Virtual Conference on Wednesday, September 20, 2023 at 2:30pm.  Additional details regarding
Sep 13, 2023 04:30 pm ET
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
CRANFORD, N.J., Sept. 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir, who passed away on Monday. Mr. Safir joined the Citius Board of Directors in 2014, providing invaluable counsel to the Citius management team for nearly a decade.  
Aug 01, 2023 09:31 am ET
Thinking about buying stock in Rigetti Computing, Virgin Galactic, Lithium Americas, Nextgen Food Robotics, or Citius Pharmaceuticals?
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RGTI, SPCE, LAC, NGRBF, and CTXR.
Jun 26, 2023 08:30 am ET
Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes
CRANFORD, N.J., June 26, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products,  today announced that it is set to be added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the annual reconstitution of Russell US Indexes, effective at the opening of the U.S. equity markets on June 26, 2023.
Jun 20, 2023 08:30 am ET
Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids
CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone
Jun 13, 2023 08:30 am ET
Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023
CRANFORD, N.J., June 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will participate in a fireside chat with Senior Biotech Research Analyst, Michael Okunewitch, at Maxim Group's Virtual Healthcare Conference on June 21, 2023.
May 12, 2023 04:30 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update
$29.1 million in cash and cash equivalents as of March 31, 2023; $15 million registered direct offering in May 2023 extends runway through May 2024
May 08, 2023 01:42 pm ET
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
CRANFORD, N.J., May 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered direct offering with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,500,001 shares of its common stock, at a purchase price of $1.20 per s
May 04, 2023 08:00 am ET
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
CRANFORD, N.J., May 4, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,500,001 shares of its common stock, at a purchase price of $1.20 per share and accompanyin
Apr 25, 2023 12:44 pm ET
Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals?
NEW YORK, April 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XPO, VIRI, ARWR, PTPI, and CTXR.
Apr 24, 2023 09:10 am ET
Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date
CRANFORD, N.J., April 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has advanced its clinical trial for Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.  Of the 92 events required to complete the trial, the Company estimates that 85 events have been achieved to date. The trial has enrolled 190 patients, of which 16 pati
Mar 30, 2023 08:30 am ET
Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company
CRANFORD, N.J., March 30, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. The U.S. Food and Drug Administration (FDA) is currently reviewing a biologics license application
Mar 13, 2023 09:15 am ET
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank
CRANFORD, N.J., March 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB.
Mar 08, 2023 07:30 am ET
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference
CRANFORD, N.J., March 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California. Citius Chairman and CEO Leonard Mazur will host one-on-one meetings with institutional investors and analysts on Monday, March 13th and Tuesday, March 14th.
Feb 10, 2023 03:30 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022; runway through February 2024
Jan 17, 2023 10:00 am ET
Sidoti's January Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can also be found at www.sidoticonference.com/events.
Jan 11, 2023 07:30 am ET
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
CRANFORD, N.J., Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.
Dec 22, 2022 03:30 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
$41.7 million in cash and cash equivalents as of September 30, 2022; extends runway through December 2023
Nov 21, 2022 07:00 am ET
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
Net operating losses converted into non-dilutive capital for ongoing R&D programs
Nov 09, 2022 07:30 am ET
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (A
Oral and Poster Presentations to Highlight Clinical Data for I/ONTAK (E7777) Study in Relapsed or Refractory Cutaneous T-cell Lymphoma on December 11, 2022
Oct 18, 2022 08:30 am ET
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022
CRANFORD, N.J., Oct. 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will be presenting at the ThinkEquity Conference on October 26, 2022.
Oct 06, 2022 04:30 pm ET
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022
CRANFORD, N.J., Oct. 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will be presenting at the Dawson James Securities Small Cap Growth Conference on October 12, 2022.
Sep 28, 2022 08:30 am ET
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous
CRANFORD, N.J., Sept. 28, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denileukin diftitox (I/ONTAK), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). I/ONTAK is a purified and more bioactive formulation of pr
Sep 15, 2022 08:30 am ET
Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute
Leading Center for Autism Education and Research has named Citius and Bartushak the 2022 Honorees for their annual Halloween Gala
Sep 08, 2022 04:30 pm ET
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET
Sep 07, 2022 08:30 am ET
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Chairman & CEO of Citius, Leonard Mazur, to present September 14, 2022 at 11:00am ET
Aug 11, 2022 04:31 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update
$48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023
Jul 12, 2022 08:07 am ET
May 25, 2022 08:47 am ET
May 18, 2022 09:30 am ET
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
CRANFORD, N.J., May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. Leonard Mazur, Chairman and CEO of Citius, will discuss the Company's recent business developments and upcoming milestones.
May 12, 2022 04:30 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update
Mino-Lok® Phase 3 trial expanded to include sites outside the U.S.; trial enrollment expected to be completed by end of 2022
May 06, 2022 09:37 am ET
May 03, 2022 10:06 am ET
Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones
CRANFORD, N.J., May 3, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments and upcoming milestones.
Apr 26, 2022 08:30 am ET
Apr 14, 2022 09:25 am ET
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
CRANFORD, N.J., April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference being held April 19-21, 2022. Leonard Mazur, Executive Chairman of Citius, will discuss recent business developments and upcoming mi
Apr 13, 2022 09:25 am ET
Apr 06, 2022 08:31 am ET
Thinking about buying stock in Citius Pharmaceuticals, BioXcel Therapeutics, Array Technologies, Gogo, or Clovis Oncology?
NEW YORK, April 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, BTAI, ARRY, GOGO, and CLVS.
Apr 06, 2022 06:50 am ET
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Supp
CRANFORD, N.J., April 6, 2022  /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today reported topline results from the pivotal Phase 3 trial of I/ONTAK (E7777), an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). The topline
Mar 03, 2022 08:15 am ET
Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences
CRANFORD, N.J., March 3, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will be presenting at two investor conferences in March 2022.
Feb 15, 2022 08:15 am ET
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
CRANFORD, N.J., Feb. 15, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Study May Proceed letter for Halo-Lido for the treatment of hemorrhoids. The Company is addressing recommendations made by the FDA and antici
Feb 11, 2022 08:31 am ET
Thinking about buying stock in Orphazyme, Yelp, Tritium DCFC, Blade Air Mobility, or Citius Pharmaceuticals?
NEW YORK, Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, YELP, DCFC, BLDE, and CTXR.
Feb 10, 2022 03:30 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update
CRANFORD, N.J., Feb. 10, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the first fiscal quarter of 2022 ended December 31, 2021.
Jan 21, 2022 08:31 am ET
Thinking about buying stock in Limelight Networks, GoHealth, Comstock Mining, Trip.com, or Citius Pharmaceuticals?
NEW YORK, Jan. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLNW, GOCO, LODE, TCOM, and CTXR.
Jan 21, 2022 07:40 am ET
Thinking about buying stock in Limelight Networks, GoHealth, Comstock Mining, Trip.com, or Citius Pharmaceuticals?
NEW YORK, Jan. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLNW, GOCO, LODE, TCOM, and CTXR.
Jan 04, 2022 08:00 am ET
Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences
CRANFORD, N.J., Jan. 4, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will be presenting at two virtual conferences in January 2022.
Dec 15, 2021 03:30 pm ET
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update
CRANFORD, N.J., Dec. 15, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the fiscal full year ended September 30, 2021.
Dec 06, 2021 08:15 am ET
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma
CRANFORD, N.J., Dec. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it has completed patient enrollment in its Pivotal Phase 3 trial of I/ONTAK, an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T
Nov 05, 2021 09:15 am ET
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls
CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strateg
Oct 25, 2021 09:15 am ET
Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients
CRANFORD, N.J., Oct. 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will host a key opinion leader (KOL) webinar on the compelling need to salvage central venous catheters in patients with central line associated blood stream infections (CLABSI) on Thursday, Nove
Oct 13, 2021 11:38 am ET
Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)
CRANFORD, N.J., Oct. 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m. ET to discuss the Company's previously announced acquisition of I/ONTAK (E7777), an improved formulation of immunotoxin ONTAK®, which was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).
Oct 06, 2021 10:40 am ET
Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
CRANFORD, N.J., Oct. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.
Oct 01, 2021 08:30 am ET
Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur
CRANFORD, N.J., Oct. 1, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University, Philadelphia, PA, which renamed the main building housing the College of Liberal Arts (CLA) to L
Sep 14, 2021 10:06 am ET
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021
CRANFORD, N.J., Sept. 14, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET.
Sep 08, 2021 09:15 am ET
Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
CRANFORD, N.J., Sept. 8, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
Sep 07, 2021 07:30 am ET
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
CRANFORD, N.J., Sept. 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's") (NYSE: RDY) to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. E7777, an engineered IL-2-diphtheria toxin fusion protein, is an improved formulation of oncology agent, ONTAK®, which was previ
Aug 12, 2021 04:30 pm ET
Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update
CRANFORD, N.J., Aug. 12, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today reported financial results for the third fiscal quarter of 2021 ended June 30, 2021, and provided a general business update.
Jul 07, 2021 07:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Citius Pharmaceuticals, Inc. - CTXR
NEW YORK, July 7, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Citius Pharmaceuticals, Inc. ("Citrus" or the "Company") (NASDAQ: CTXR).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Jul 07, 2021 10:45 am ET
Thinking about buying stock in Exela Technologies, Vivos Therapeutics, Cloudera, Citius Pharmaceuticals, or Powerbridge Technologies?
NEW YORK, July 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, VVOS, CLDR, CTXR, and PBTS.
Jul 07, 2021 09:20 am ET
Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones
CRANFORD, N.J., July 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today provided a business update for the six-month period ended June 30, 2021 and reported on recent corporate developments.
Jul 02, 2021 10:45 am ET
Thinking about buying stock in ContextLogic, Exela Technologies, Citius Pharmaceuticals, Overseas Shipholding, or Cerevel Therapeutics?
NEW YORK, July 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, XELA, CTXR, OSG, and CERE.
Jul 01, 2021 11:00 am ET
Thinking about buying stock in Exela Technologies, Marin Software, Citius Pharmaceuticals, Verb Technology, or Li Auto?
NEW YORK, July 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, MRIN, CTXR, VERB, and LI.
Jul 01, 2021 09:00 am ET
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned
CRANFORD, N.J., July 1, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that following a unblinded data review of safety and efficacy, the independent Data Monitoring Committee (DMC) for the Mino-Lok® Phase 3 Pivotal Superiority Trial has recommended proceeding with the trial as planned. The DMC did
Jun 24, 2021 08:30 am ET
Thinking about buying stock in Arcus Biosciences, Capricor Therapeutics, Orphazyme, Sundial Growers, or Citius Pharmaceuticals?
NEW YORK, June 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RCUS, CAPR, ORPH, SNDL, and CTXR.
Jun 23, 2021 08:30 am ET
Thinking about buying stock in ConforMIS, Citius Pharmaceuticals, Clover Health, Capricor Therapeutics, or Dare Bioscience?
NEW YORK, June 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CFMS, CTXR, CLOV, CAPR, and DARE.
Jun 22, 2021 10:45 am ET
Thinking about buying stock in ContextLogic, Adial Pharmaceuticals, Geron Corp, Orphazyme, or Citius Pharmaceuticals?
NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, ADIL, GERN, ORPH, and CTXR.
Jun 17, 2021 10:50 am ET
Thinking about buying stock in Citius Pharmaceuticals, New Oriental Education, Cellect Biotechnology, Novan, or Seanergy Maritime?
NEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, EDU, APOP, NOVN, and SHIP.
Jun 16, 2021 10:50 am ET
Thinking about buying stock in ContextLogic, Senseonics, BlackBerry, Seanergy Maritime, or Citius Pharmaceuticals?
NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, SENS, BB, SHIP, and CTXR.
Jun 15, 2021 09:20 am ET
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS
CRANFORD, N.J., June 15, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ARDS Scientific Advisory Board (SAB), e
Jun 08, 2021 09:00 am ET
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
CRANFORD, N.J., June 8, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that the next planned interim analysis in its Phase 3 trial of Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related blood stream infections (CRBSIs/CLABSIs) has been scheduled for the end of
Feb 25, 2021 09:45 am ET
Thinking about buying stock in BlackBerry, Express, Norwegian Cruise Line, Citius Pharmaceuticals, or Verizon?
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, EXPR, NCLH, CTXR, and VZ.
Feb 24, 2021 10:30 am ET
Thinking about buying stock in Workhorse Group, Globalstar, Palantir Technologies, Marathon Oil, or Citius Pharmaceuticals?
NEW YORK, Feb. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WKHS, GSAT, PLTR, MRO, and CTXR.
Feb 22, 2021 07:30 am ET
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, CANF, CFMS, CTXR, and VUZI.
Feb 19, 2021 03:47 pm ET
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
CRANFORD, N.J., Feb. 19, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed its previously announced sale of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.
Feb 19, 2021 07:30 am ET
Thinking about buying stock in Energous Corp, Casa Systems, Citius Pharmaceuticals, Creative Realities, or Precision BioSciences?
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, CASA, CTXR, CREX, and DTIL.
Feb 18, 2021 09:55 am ET
Thinking about buying stock in Sundial Growers, AMC Entertainment, Northern Dynasty Minerals, Citius Pharmaceuticals, or Hepion Pharmaceuticals?
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, AMC, NAK, CTXR, and HEPA.
Feb 17, 2021 09:55 am ET
Thinking about buying stock in Diffusion Pharmaceuticals, Northern Dynasty Minerals, Zomedica, Sundial Growers, or Citius Pharmaceuticals?
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DFFN, NAK, ZOM, SNDL, and CTXR.
Feb 16, 2021 11:28 pm ET
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
CRANFORD, N.J., Feb. 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registe
Feb 16, 2021 08:15 am ET
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021
CRANFORD, N.J., Feb. 16, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today issued a shareholder letter providing a corporate update on the Company's recent achievements and anticipated milestones for 2021.
Feb 08, 2021 07:35 am ET
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 4th Small and Microcap Showcase are now available for on-demand viewing.
Feb 02, 2021 07:00 am ET
Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4
CRANFORD, N.J., Feb. 2, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, will present at the upcoming Virtual Investor Conferences Small and Microcap Showcase on Thursday, February 4, 2021. Citius Chairman of the Board Leonard Mazur will present an update on the Company's lead product candidate MinoLok, currently in Phase 3 trials, and an overview of three other active programs.
Jan 28, 2021 07:35 am ET
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
Company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Jan 28, 2021 07:35 am ET
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small and Microcap Showcase.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, February 4th  with the first live webcast at 9:00 AM ET.
Jan 27, 2021 12:00 pm ET
Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market
CRANFORD, N.J., Jan. 27, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed on the sale to certain institutional and accredited investors of approximately $20.0 million through the issuance of an aggregate of 15,455,960 shares of its common stock and warrants to purchase up to an aggregate of 7,727,980 shares of common stock, at a purchase price of $1.294 per share of common stock and associated warrant in a pr
Jan 25, 2021 06:00 am ET
Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market
CRANFORD, N.J., Jan. 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $20.0 million through the issuance of an aggregate 15,455,960 shares of its common stock and warrants to purchase up to an aggregate of 7,727,980 shares of common stock, at a purchase price of $1.294 per share of common stock
Jan 06, 2021 08:00 am ET
Citius Pharmaceuticals to Present Update on Proprietary Product Candidates at Two Virtual Conferences in January
CRANFORD, N.J., Jan. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will be presenting at two virtual investor conferences during the month of January 2021.
Dec 15, 2020 08:40 am ET
Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19
CRANFORD, N.J., Dec. 15, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has conducted a series of webinars to provide trial updates, discuss patient identification parameters, the challenges of running a trial in today's Covid-19 environment, and the role Mino-Lok may play  in the treatment of Central Line Associated Blood Stream Infections (CLABSIs).  Presentations were made by infectious disease experts from The Uni
Dec 09, 2020 08:40 am ET
Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap
CRANFORD, N.J., Dec. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced its receipt of a written response and guidance from the U.S. Food and Drug Administration (FDA) Division of Anti-Infective Products to the Company's Pre-Investigational New Drug (Pre-IND) consultation request for its Mino-Wrap briefing package.  Through its global license agreement with the The University of Texas MD Anderson Cancer Center, Citius is developing
Dec 08, 2020 08:15 am ET
Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS")
CRANFORD, N.J., Dec. 8, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced interim data from a proof-of-concept ("POC") large animal study of its proprietary induced mesenchymal stem cell ("i-MSC") therapy for acute inflammatory respiratory conditions including COVID-19 related Acute Respiratory Distress Syndrome ("ARDS"). The available results of i-MSC therapy in the study show improvement in critical parameters, such as improved oxygenati
Dec 03, 2020 02:30 pm ET
Citius Pharmaceuticals to Present Corporate Update at Benzinga Global Small Cap Conference on December 8
CRANFORD, N.J., Dec. 3, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will be participating in the Benzinga Global Small Cap Conference being held virtually on December 8 and 9, 2020. Citius Chairman Leonard Mazur will present at 11:30 am ET on Tuesday, December 8, 2020, and will host one-on-one investor meetings.
Nov 30, 2020 08:15 am ET
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components
CRANFORD, N.J., Nov. 30, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced the completion of a Boston Analytical study "Silicone Disk Method for In Vitro Assessment of Antimicrobial Activity Against Resistant Staphylococcal Biofilms by Minocycline-EDTA-Ethanol and EDTA-Ethanol Lock Solutions." This study demonstrated that all three components of Mino-Lok (30 mg/mL EDTA, 19.5% ethanol and 1 mg/mL minocycline) were superior to EDT
Nov 10, 2020 08:30 am ET
Citius Pharmaceuticals to Present at Virtual Fall Investor Summit
CRANFORD, N.J., Nov. 10, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that management will present at the Virtual Fall Investor Summit to be held virtually on November 16-18, 2020. Leonard Mazur, Chairman of Citius, will deliver a corporate overview of the Company on Monday, November 16, at 1:00 p.m. Eastern Time. Mr. Mazur will also conduct virtual one-on-one meetings with investors during the conference.
Nov 09, 2020 08:30 am ET
Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference
CRANFORD, N.J., Nov. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will present at the H.C. Wainwright 6th Annual Israel Conference to be held virtually on November 12, 2020. Myron Holubiak, Chief Executive Officer of Citius, will provide an update of the Company's products under development and provide an overview on Thursday, November 12, at 2:30 p.m. Eastern Time. Mr. Holubiak will also conduct virtual one-on-one meetings
Oct 27, 2020 09:00 am ET
Citius Pharmaceuticals Issues October 2020 Letter to Shareholders
CRANFORD, N.J., Oct. 27, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has issued an October 2020 Letter to Shareholders. The letter addresses recent updates on the Company's business and clinical developments and news for its pipeline of products.
Oct 13, 2020 07:30 am ET
Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions
CAMBRIDGE, Mass., Oct. 13, 2020 /PRNewswire/ -- Novellus Therapeutics ("Novellus"), an engineered cellular medicines company, announced today that it has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, Inc., a newly formed subsidiary of Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products. NoveCite will develop and commercialize Novellus's iMSCs to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("AR
Aug 31, 2020 05:00 pm ET
LD Micro 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 05, 2020 09:00 pm ET
Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
CRANFORD, N.J., Aug. 5, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 7,964,804 shares of common stock of the Company, at a price to the public of $1.05 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about Augus
Aug 05, 2020 05:32 pm ET
Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
CRANFORD, N.J., Aug. 5, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,714,286 shares of common stock of the Company, at a price to the public of $1.05 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 04, 2020 08:17 am ET
Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
CRANFORD, N.J., Aug. 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products announced progress in the development of Mino-Wrap, a novel approach to reducing post-operative infections associated with surgical implants.
Jul 22, 2020 10:30 am ET
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
CRANFORD, N.J., July 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today the formation of the Citius ARDS (Acute Respiratory Distress Syndrome) Scientific Advisory Board to provide the company expert guidance on  its planned development of induced mesenchymal stem cells (iMSCs) under option from Novellus, Inc. to treat and reduce the severity of acute respiratory distress syndrome (ARDS) associated with COVID -19. 
Jul 20, 2020 02:00 pm ET
Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event
CRANFORD, N.J., July 20, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Accredited Investor Virtual Event that is being held July 22 – 24, 2020.
Jul 14, 2020 08:47 am ET
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
CRANFORD, N.J., July 14, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Myron S. Czuczman, M.D., has joined the company as Chief Medical Officer (CMO) and Executive Vice President. Dr. Czuczman was most recently Therapeutic Area Head, Vice President, Clinical Research and Development Global Lymphoma/CLL Program at Celgene Corporation.  At Celgene, he was responsible for worldwide clinical development in Lymphoma/CLL and
Jul 13, 2020 08:15 am ET
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
CRANFORD, N.J., July 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it received notice from The Nasdaq Stock Market LLC ("NASDAQ") on July10, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NAS
Jun 30, 2020 09:31 am ET
Thinking about buying stock in Citius Pharmaceuticals, Bloom Energy Corp, Nautilus Inc, Plug Power, or Hexo Corp?
NEW YORK, June 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, BE, NLS, PLUG, and HEXO.
Jun 29, 2020 09:07 am ET
Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
CRANFORD, N.J., June 29, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that its CEO, Myron Holubiak, is scheduled to appear as a featured guest on TD Ameritrade Network's The Watch List with host Nicole Petallides on Tuesday, June 30, 2020 at 1:20pm ET. Interested parties may view the live interview at https://tdameritradenetwork.com/.
Jun 29, 2020 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...
Jun 26, 2020 09:31 am ET
Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL.
Jun 26, 2020 09:00 am ET
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVI
CRANFORD, N.J., June 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.
Jun 23, 2020 08:49 am ET
Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020
Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company...
Jun 22, 2020 01:17 pm ET
Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum
CRANFORD, N.J., June 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Chief Executive Officer Myron Holubiak will deliver a virtual presentation at the Life Sciences Investor Forum on Thursday, June 25, 2020 at 11:00 AM ET. 
Jun 02, 2020 09:30 am ET
Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
CRANFORD, N.J., June 2, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has received positive feedback from the Food and Drug Administration (FDA) on its proposed catheter compatibility studies for the Company's Mino-Lok® therapy. The studies, if and when successfully completed, should allow Mino-Lok to be labeled for use with all commercially available central venous catheters (CVCs) and peripherally inserted central
May 26, 2020 08:15 am ET
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
CRANFORD, N.J., May 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it is providing free access to Mino-Lok® for healthcare providers under an Expanded Access protocol to ease the burden associated with the COVID-19 pandemic.
May 18, 2020 02:30 pm ET
Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
CRANFORD, N.J., May 18, 2020 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced registered direct offering priced at-the-market under Nasdaq rules.  In the offering, Citius sold 7,058,824 shares of its common stock, at a purchase price per share of $1.0625. Additionally, Citius issued to the investors unregistered warrants to purchase up to 3,529,412 shares of its common stock. 
May 14, 2020 09:00 am ET
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
CRANFORD, N.J., May 14, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 7,058,824 shares of its common stock, at a purchase price per share of $1.0625 for gross proceeds of approximately $7.5 million, in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, Citius has also agreed to issue to the investors unregi
May 13, 2020 08:15 am ET
Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
CRANFORD, N.J., May 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that data on NoveCite MSCs will be presented this week at the American Society of Gene and Cell therapy (ASGCT) annual meeting. NC-MSCs are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. Earlier this year, Citius signed an exclusive option agreement to in-license NC-MS
May 12, 2020 08:00 am ET
Citius Pharmaceuticals Issues May 2020 Shareholder Letter
CRANFORD, N.J., May 12, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that the Company has issued its May 2020 Shareholder Letter.  The letter highlights the Company's exclusive option to license a novel stem-cell therapy to treat acute respiratory distress syndrome (ARDS) associated with COVID-19, and the clinical progress of the Company's core products: Mino-Lok®, Mino-Wrap™, and Halo-Lido.
Apr 27, 2020 09:30 am ET
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
CRANFORD, N.J., April 27, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell th
Apr 01, 2020 08:07 am ET
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
CRANFORD, N.J., April 1, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc., a preclinical-stage biotechnology company based in Cambridge, MA.
Mar 26, 2020 09:06 am ET
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
CRANFORD, N.J., March 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the publication of an in vitro study for Mino-Lok®, the Company's antibiotic lock solution used to treat patients with central line associated blood stream infections (CLABSIs) and catheter-related bloodstream infections (CRBSIs), in the March 2020 issue of Antimicrobial Agents and Chemotherapy.  The article, titled "Minocycline-EDTA-Ethanol Antimicrobial Ca
Mar 18, 2020 09:46 am ET
Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit
CRANFORD, N.J., March 18, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that Chief Executive Officer Myron Holubiak will deliver a virtual presentation at the Spring Investor Summit on Wednesday, March 25, 2020 at 8:50 AM ET. 
Mar 03, 2020 04:45 pm ET
Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City
NEW YORK, NY / ACCESSWIRE / March 3, 2020 / Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), is a specialty pharmaceutical company dedicated to the development and commercialization of drug products that address important unmet medical needs, will be presenting at this year's Spring Investor Summit on March 25th-26th in New York City.
Jan 27, 2020 08:00 am ET
Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses
Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks releases a special report on the opportunity within the specialty drug segment of the sector to address viral outbreaks and bacterial resistance, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR).
Nov 08, 2019 07:00 am ET
Citius Pharmaceuticals Issues Corporate Update
CRANFORD, N.J., Nov. 8, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:  CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that the Company has issued its October 2019 Corporate Update Letter.  The Letter highlights the progress of the Company's product candidates Mino-Lok®, Mino-Wrap™, and Halo-Lido, along with details on its strategic goals to develop breakthrough technologies to improve and enhance the lives of patients.
Oct 24, 2019 08:00 am ET
Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference
CRANFORD, N.J., Oct. 24, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on developing adjunctive cancer care and critical care drug products, announced today that the Company will present at the 5th Annual Dawson James Small Cap Growth Conference on Tuesday, Oct 29, 2019 at 4:30-4:50 PM ET in Track 2 - Preserve Ballroom B. The conference is being held at the Wyndham Grand Hotel in Jupiter, Florida on October 28-29, 2019.  
Oct 15, 2019 08:00 am ET
Citius Pharmaceuticals to Present at the MicroCap Rodeo
CRANFORD, N.J., Oct. 15, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the MicroCap Rodeo on Oct 16th at 9:45-10:15 AM in room 416B. The conference is being held at the Hilton Austin in Austin, Texas on October 15-16, 2019.
Oct 07, 2019 08:30 am ET
Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial
CRANFORD, N.J., Oct. 7, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that the data cutoff for the most recent patient treated and completing 8 weeks of observation has been reached. The Company is preparing the submission to the independent Drug Monitoring Committee ("DMC") for review and evaluation.
Oct 03, 2019 07:00 am ET
Citius Provides Update on Activities From IDWeek 2019
CRANFORD, N.J., Oct. 3, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported Company activities at ID Week, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).
Sep 27, 2019 11:28 am ET
Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market
CRANFORD, N.J., Sept. 27, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced underwritten at-the-market offering of 7,821,230 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,821,230 shares of Common Stock (the Offering). Each share of Common Stock (or Common Stock equivalent) was sold together with a common warrant to pur
Sep 25, 2019 07:00 am ET
Citius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market
CRANFORD, N.J., Sept. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten offering of 7,821,230 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,821,230 shares of Common Stock (the Offering), priced at-the-market. Each share of Common Stock (or Common Stock equivalent) is being sold together with a common warrant to purchase one
Sep 04, 2019 06:55 am ET
Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study
CRANFORD, N.J., Sept. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that the FDA responded to the Company's proposal to refine the endpoints in the current Phase 3 pivotal trial for Mino-Lok.
Aug 29, 2019 08:00 am ET
Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.
CRANFORD, N.J., Aug. 29, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will be presenting at the 4th annual Disruptive Growth Conference on Wednesday, September 4th at 3:40PM EST in Presentation Room A/B.  During the conference, Executive Chairman, Mr. Leonard Mazur will be giving the presentation as well as answering questions from investors.
Jul 30, 2019 08:00 am ET
Citius Provides Developmental Plans for Mino-Wrap
CRANFORD, N.J., July 30, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported the Company's decision to develop Mino-Wrap as a drug through the Investigational New Drug ("IND") process. The FDA's IND program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines before a marketing application for the drug has been approved.
May 13, 2019 08:47 am ET
Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris
CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a report today on the in vitro efficacy of Mino-Lok against various strains of Candida auris. 
May 01, 2019 08:00 am ET
Citius Pharmaceuticals to Present at the ThinkEquity Conference
CRANFORD, N.J., May 1, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 8:30AM ET. The conference is being held at The Mandarin Oriental Hotel in New York City.
Apr 30, 2019 09:45 am ET
Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy
CRANFORD, N.J., April 30, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a report today on the clinical efficacy of Mino-Lok against various pathogens that are encountered in colonized catheters that cause bacteremia, either central line associated bloodstream infection ("CLABSI") or catheter related bloodstream infection ("CRBSI"). In a meta-analysis of two separate studies conducted in four institutions in four different countries (see table), it was
Apr 04, 2019 08:30 am ET
Citius Pharmaceuticals Successfully Raises $5.3 Million
CRANFORD, N.J., April 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company")("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company completed an at-the-market offering for $5.3 million in gross proceeds, with insiders responsible for supporting over 37% of the raise. Mr. Leonard Mazur, Executive Chairman of Citius Pharmaceuticals, invested $1.8 million and Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals, invested $200,000 in the Company to bring the deal into fruition
Apr 01, 2019 09:00 am ET
Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market
CRANFORD, N.J., April 1, 2019 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 3,430,421 shares of its common stock, at a purchase price per share of $1.545 for gross proceeds of approximately $5.3 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to p
Jan 25, 2019 07:00 am ET
Citius Pharmaceuticals to Present at NobleCon15 Investor Conference
CRANFORD, N.J., Jan. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that its Vice President of Corporate Development, Andrew Scott, will present at NobleConXV - Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 28th at 10:00am Eastern Standard Time in Studio 2.
Jan 08, 2019 08:00 am ET
Citius Licenses Mino-Wrap From MD Anderson Cancer Center
CRANFORD, N.J., Jan. 8, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that a definitive license agreement has been reached with MD Anderson Cancer Center ("MDACC") to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. The initial product called "Mino-Wrap", or CITI 101, is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) i
Jan 04, 2019 09:45 am ET
Citius Pharmaceuticals to Present at Biotech Showcase Investor Conference
CRANFORD, N.J., Jan. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that its Chief Executive Officer, Mr. Myron Holubiak, will present at the Biotech Showcase Investor Conference. The conference will be held on January 7-9, 2019 at the Hilton San Francisco Union Square.
Dec 19, 2018 08:45 am ET
Citius Pharmaceuticals Provides Updates on Mino-Lok® and CITI-002
CRANFORD, N.J., Dec. 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report today on Mino-Lok® and CITI-002.
Dec 10, 2018 07:35 am ET
Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Dec 10, 2018 07:35 am ET
Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Dec 04, 2018 07:35 am ET
Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th
Company executives share vision, answer questions live at VirtualInvestorConferences.com
Dec 04, 2018 07:35 am ET
Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th
Company executives share vision, answer questions live at VirtualInvestorConferences.com
Nov 30, 2018 07:00 am ET
Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event
CRANFORD, N.J., Nov. 30, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that its Executive Chairman, Leonard Mazur, will present at the 11th Annual LD Micro Main Event. The conference will be held on December 4-6, 2018 at the Luxe Sunset Blvd Hotel, Los Angeles.
Nov 29, 2018 03:35 pm ET
Citius Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 6
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Nov 29, 2018 03:35 pm ET
Citius Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 6
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Oct 25, 2018 08:00 am ET
Citius Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
CRANFORD, N.J., Oct. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Executive Chairman, Leonard Mazur, will present at the Dawson James 2018 Small Cap Growth Stock Conference.  The Conference will be held on October 30, 2018 at the Wyndham Grand Hotel in Jupiter, Florida.
Oct 23, 2018 08:00 am ET
Citius Reports On Activities During Infectious Disease Week 2018
CRANFORD, N.J., Oct. 23, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, reported on its recent activities in San Francisco. The meetings occurred at the same time as IDWeek 2018, but were not an official part of the IDWeek program. 
Sep 27, 2018 08:00 am ET
Citius Announces The Publication Of European Patent For Mino-Lok®
CRANFORD, N.J., Sept. 27, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received official notification from MD Anderson Cancer Center ("MDACC") that the European Patent Application (No. 16806326.1) for Mino-Lok with Enhanced Stability was published (September 12, 2018) under serial number 3370794. This patent which already received a Notice of Allowance from the US Patent and Trademark Office in July of 2018, and which patent was issued by the USPTO
Sep 25, 2018 08:00 am ET
Citius Announces The Issuance Of The Patent On The Advanced Stability Of Mino-Lok® By USPTO
CRANFORD, N.J., Sept. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") will issue United States Patent Number 10/086,114 entitled "Antimicrobial Solutions with Enhanced Stability" on October 2, 2018.
Aug 15, 2018 08:00 am ET
Citius Pharmaceuticals Successfully Raises $10 Million
CRANFORD, N.J., Aug. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company completed the largest capital raise in its history of $10 million, and insiders were responsible for supporting 50% of the raise. Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals, invested $1 Million in the Company and Mr. Leonard Mazur, Executive Chairman of Citius Pharmaceuticals invested $4 Million to bring the deal into fruition.
Aug 13, 2018 05:00 pm ET
Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market
CRANFORD, N.J., Aug. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced underwritten at-the-market offering of 7,843,138 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,843,138 shares of Common Stock (the Offering). Each share of Common Stock (or Common Stock equivalent) was sold together with a common warrant to purchase one share of Commo
Aug 09, 2018 06:00 am ET
Citius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market
CRANFORD, N.J., Aug. 9, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten offering of 7,843,138 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,843,138 shares of Common Stock (the Offering), priced at-the-market. Each share of Common Stock (or Common Stock equivalent) is being sold together with a common warrant to purchase one share of Common Stock at
Jul 24, 2018 08:00 am ET
Citius Announces The Notice Of Allowance From The USPTO On The Advanced Stability Patent Application For Mino-Lok®
CRANFORD, N.J., July 24, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") has reviewed and examined the patent application US 2017/051373 A1 and that it is allowed for issuance as a patent.
Jul 13, 2018 10:48 am ET
Citius Announces Key Addition to its Scientific Advisory Board
CRANFORD, N.J., July 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Dr. Lawrence Mermel has accepted a position on the Citius Scientific Advisory Board.
Jul 09, 2018 08:00 am ET
Citius Provides Clinical Update And Progress Of The Mino-Lok® Phase 3 Trial
CRANFORD, N.J., July 9, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report on the progress of the Mino-Lok Phase 3 clinical program. The Mino-Lok Phase 3 Trial is planned to enroll 700 patients in 50 participating institutions, all located in the U.S. There will be interim analyses at the 50% and 75% point of the trial as measured by the number of patients treated.
Jun 19, 2018 08:00 am ET
Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark
CRANFORD, N.J., June 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Mino-Lok® is now a registered trademark with the U.S. Patent and Trademark Office.  Citius' Mino-Lok® product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a challenge.
Mar 29, 2018 08:00 am ET
Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market
CRANFORD, N.J., March 29, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 669,504 shares of its common stock, at a purchase price per share of $2.9850 for gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to p
Mar 06, 2018 07:00 am ET
Citius Reports Progress in Hemorroid Treatment Program
CRANFORD, N.J., March 6, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that the Company is selecting a higher potency corticosteroid in its steroid/anesthetic topical formulation program for the treatment of hemorrhoids. The original topical preparation, CITI-001, was a combination of hydrocortisone acetate and lidocaine hydrochloride. The new formulation, CITI-002, will combine lidocaine with the higher potency corticosteroid for symptomatic relief of the pain and discomfort of hemorrhoids. While not us
Feb 15, 2018 07:00 am ET
Citius Announces Enrollment Of First Patient In The Mino-Lok™ Phase 3 Trial
CRANFORD, N.J., Feb. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that yesterday the first patient was randomized into the Mino-Lok Phase 3 clinical trial for catheter related bacteremias ("CRBSIs") at the Henry Ford Health System in Detroit, Michigan. When fully-recruited, it is planned that there will be 700 patients enrolled in 50 participating institutions, throughout the U.S.
Feb 13, 2018 07:00 am ET
Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias
CRANFORD, N.J., Feb. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, published the proceedings of a roundtable of experts today, entitled, "Treating CLABSI: A Clinical and Economic Challenge".
Jan 31, 2018 07:00 am ET
Citius Pharmaceuticals to Present at BIO CEO & Investor Conference
CRANFORD, N.J., Jan. 31, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it will be presenting at the BIO CEO & Investor Conference. The conference will be held February 12-13, 2018 at the New York Marriott Marquis. The CTXR presentation will take place at 10:30 AM (Ziegfeld Room) on Tuesday, February 13, 2018.  Mr. Leonard Mazur, Executive Chairman of Citius, and Mr. Myron Holubiak, President and CEO, will be giving the presentation and meeting
Jan 04, 2018 07:00 am ET
Citius Pharmaceuticals to Present at Biotech Showcase™ 2018
CRANFORD, N.J., Jan. 4, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it will be presenting at the Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at the Hilton San Francisco Union Square. The CTXR presentation will take place at 2:00 PM on Monday, January 8. Mr. Leonard Mazur, Executive Chairman of Citius, and Myron Holubiak, President and CEO, will be giving the presentation and meeting with investors throughout the week.
Dec 18, 2017 07:00 am ET
Citius Announces $6 Million Registered Direct Offering Priced At-the-Market
CRANFORD, N.J., Dec. 18, 2017 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,280,360 shares of its common stock, at a purchase price per share of $4.6925, for gross proceeds of approximately $6 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to p
Dec 06, 2017 07:00 am ET
Mino-Lok™ Phase 3 Clinical Trial Supplies Shipped to Sites
CRANFORD, N.J., Dec. 6, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, has announced that clinical trial supplies of Mino-Lok (minocycline/edetate/ethanol) have been sent to the University of Chicago Medical Center, and the Henry Ford Health System in Detroit, the first 2 clinical trial sites for the Mino-Lok phase 3 pivotal trial. When fully recruited, it is planned that there will be 50 participating sites, all located in the U.S.
Nov 14, 2017 08:00 am ET
Inserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is Unnecessary
CRANFORD, N.J., Nov. 14, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, noted that a recent paper presented at the Infectious Disease Society of America (IDSA) meeting in early October (ID Week - 2017) showed that as many as half of the patients having their central venous catheters (CVCs) removed or inserted experience distress and/or catheter threading pressure, and about a third felt these symptoms to be severe.
Nov 07, 2017 08:00 am ET
International Study at MD Anderson Sister Institutions Supports Mino Lok™ Phase 2b Results: Poster Presented at ID Week
CRANFORD, N.J., Nov. 7, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that international data on Mino Lok™ was recently presented at the ID Week Conference in San Diego, California.
Oct 31, 2017 09:00 am ET
Citius Pharmaceuticals, Inc. Receives "Fast Track" Designation By FDA For Mino-Lok™ Investigational Trial
CRANFORD, N.J., Oct. 31, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today it has received official notice from the U. S. Food and Drug Administration ("FDA") that the investigational program for Mino-Lok™ is designated "Fast Track".  Mino-Lok is a catheter lock solution that has entered phase 3 trials for an adjunctive treatment for catheter related blood stream infection ("CRBSI"). Fast Track is a designation by the FDA of an investiga
Oct 17, 2017 10:00 am ET
Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference
CRANFORD, N.J., Oct. 17, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Chief Executive Officer, Mr. Myron Holubiak, will present at the Dawson James 2017 Small Cap Growth Stock Conference.  The Conference will be held on October 19, 2017 at the Wyndham Grand Hotel in Jupiter, Florida.
Oct 11, 2017 10:00 am ET
Citius Pharmaceuticals Issues Shareholder Letter
CRANFORD, N.J., Oct. 11, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company mailed a letter to its shareholders updating them on recent developments, financial results, and new business opportunities. Highlights include:
Sep 05, 2017 08:00 am ET
Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting
CRANFORD, N.J., Sept. 5, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today it has received feedback from the U. S. Food and Drug Administration regarding amendments to the phase 3 study plan for Mino-Lok™, an adjunctive treatment for catheter related blood stream infection. There are currently no approved therapies to salvage infected central venous catheters ("CVCs").  Citius is currently recruiting sites for a phase 3 trial of Mino-Lok
Aug 08, 2017 12:25 pm ET
Citius Pharmaceuticals, Inc. Announces Closing of Public Offering
CRANFORD, N.J., Aug. 8, 2017 /PRNewswire/ -- CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR),  a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the closing of its previously announced underwritten public offering of 1,648,484 shares of its common stock and warrants to purchase up to an aggregate of 1,648,484 shares of its common stock at a combined offering price of $4.125. In addition, the underwriters partially exercised the over-allotment to purchase an additional 247,272 warrants. The warrants have a per share exercise pric
Aug 03, 2017 10:31 am ET
Citius Pharmaceuticals, Inc. Prices $6,800,000 Public Offering And Listing On The Nasdaq Capital Market
CRANFORD, N.J., Aug. 3, 2017 /PRNewswire/ -- CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten public offering of 1,648,484 shares of its common stock and warrants to purchase up to an aggregate of 1,648,484 shares of its common stock at a combined offering price of $4.125 per share. The warrants will have a per share exercise price of $4.125, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Citi
Jun 13, 2017 11:37 am ET
Citius Pharmaceuticals Presents At The 2017 Marcum MicroCap Conference
NEW YORK, June 13, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, is presenting to investors at the 2017 Marcum MicroCap Conference on June 15. The Marcum conference is a highlight on the annual investment community calendar in New York City.
Jun 08, 2017 06:00 pm ET
Citius Pharmaceuticals Announces Reverse Stock Split
CRANFORD, N.J., June 8, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on critical care drug products, announced today a reverse stock split of its outstanding common stock at a ratio of 1-for-15 effective at market open on Friday June 9, 2017. The reverse stock split will reduce the number of outstanding shares of the Company's common stock from approximately 75.8 million shares to approximately 5.05 million shares.  Upon completion of the split, management will seek to secure listing on a senior exchange.  A senior ex
Jun 06, 2017 01:30 pm ET
Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational
LOS ANGELES, June 6, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6, at 10:00 AM PDT / 1:00 PM EDT. Leonard Mazur, Executive Chairman of Citius, will be giving the presentation and meeting with investors.
Mar 23, 2017 08:00 am ET
Citius Pharma Announces Addition of South America to World License
CRANFORD, N.J., March 23, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™.  South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center ("MDACC"), and Leonard-Meron Biosciences, Inc. ("LMB"), a wholly owned subsidiary of Citius Ph
Mar 01, 2017 07:00 am ET
Survey Shows Catheter Salvage in CLABSI Patients Highly Desirable
CRANFORD, N.J., March 1, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, obtained top line data from a survey of 31 physicians clearly showing a need for catheter salvage in patients with indwelling central venous lines, especially when the catheter is a tunneled or an implanted port. There were 19 Infectious Disease experts and 12 Intensivists surveyed who all agreed that salvage would be preferable to catheter exchange fearing that catheter misplacements, blood
Feb 10, 2017 07:00 am ET
Citius Pharmaceuticals to Present at BIO CEO & Investor Conference
CRANFORD, N.J., Feb. 10, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that its Chief Executive Officer (CEO), Myron Holubiak, will present at the BIO CEO & Investor Conference. The Conference will be held on February 13-14, 2017 at the Waldorf Astoria, New York, New York.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.